Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...

AnaptysBio plans to advance rosnilimab for RA, with a program update expected in the first half of 2026. Read why ANAB stock ...

One way we can prevent that is by eating certain foods. She recommends following the MIND diet since it has been found to be the most beneficial for brain health and Alzheimer’s prevention. It ...

Kyverna Therapeutics (KYTX) is rated a strong buy with promising KYV-101 Phase 2 data and near-term catalysts. Read here for ...

Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected ...

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic ...

No drugs are specifically indicated for MASLD, but the FDA has granted accelerated approval to two drugs for non-cirrhotic ...

Byrna Technologies ( ($BYRN) ) has shared an announcement. Byrna Technologies Inc. has released an updated investor presentation, which is ...

Katie Wilson will be Seattle's next mayor, having garnered a mathematically-insurmountable lead over Mayor Bruce Harrell, ...

Across Africa, central banks are walking a tightrope between curbing inflation and stimulating growth, with policy rates revealing just how ...

Earnings call 3i Group reported a 13% total return for the half-year, with NAV per share rising to £28.57, up from £22.61 YoY. Private equity delivered a 14% gross investment return, led by Action’s ...

SAN MATEO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional ...